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1. Introduction  
The risk of renal transplant recipients to develope malignant disease is significantly higher 
than these in general population. The incidence of malignancy is estimated to be around 15-
20% of renal recipients 10 years after renal transplantation and increases as high as 49.6% 
after 20 years.(Alberu, 2010; Kapoor, 2008; Penn, 2000; Gaya, et al, 1995). The most common 
malignancies are skin carcinomas and lymphomas (Lutz & Heemann, 2003). The 
immunosuppressive agents play an important role in contributing to such happenings. 
United Network for Organ Sharing (UNOS) registry data demonstrated that mammalian 
target of rapamycin (mTOR) inhibitors is associated with a reduced incidence of tumors 
compared to regimens that do not utilize mTOR-inhibitor (Rama & Grinyo, 2010). In UK 
transplant registry (UKTR) database, 1.9% of patients were reported to have a subsequent 
urological malignancy after renal transplantation (Besarani & Cranston, 2007).  
2. Urothelial carcinoma after kidney transplantation 
2.1 Urologic cancer after kidney transplantation 
With increasing age of donor and recipient, the risk of post-transplant malignancy including 
genitourinary cancers is increasing. Urologists have an increasing likelihood of treating 
these cases. Melchior et al reported 29 urological de novo malignancies [12 renal cell 
carcinoma, 8 urothelial carcinoma (6 bladder, 2 renal pelvis), 7 carcinoma of the prostate, 2 
seminoma] developed in a series of 802 patients after renal transplantation (Melchior et al, 
2011). The overall incidence of urological neoplasms varied from 0.38% to 3.1% (Ravaud et 
al, 2010). Urothelial carcinoma (UC) of the bladder is not common in Western countries 
(Master et al, 2004) while it is the most common genitourinary tumor following kidney 
transplantation in China, Iran, Taiwan and Thailand (Einollahi et al, 2009; Ativitavas et al, 
2008). Among the Chinese population, urological malignancies, especially UC, are an 
important complication after renal transplanatation (Zhou et al, 2006). In some areas around 
the world, the incidence of UC (or “transitional cell carcinoma, TCC”) of the urinary tract in 
renal transplant recipients is singificantly higher than other parts of world. Majority of 
previous studies showing increased incidence of UC in renal transplant recipients came 
from Taiwan where it was attributed to environmental and occupational factors (Husain et 
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al, 2009). Urinary tract UC is the leading de novo malignancy following renal 
transplantation in Taiwan followed by hepatoma (Wang et al, 2010; Hung et al, 2007; Liao et 
al, 2004; Kang et al, 2004; Kao et al, 2003; Wang et al, 2002; Yang et al, 1998). This is very 
different from the Western countries or other Asian countries such as Japan, Korea. 
Wu at al from Taiwan reported that as high as 17.5% of renal transplanta recipients 
developed urinary tract UC at 10 years after transplantation. Compared with the general 
population in Taiwan, the standardized mortality ratio (SMR) was 398.4 among renal 
transplant recipients and the SMR was much higher among female patients (875.6). Painless 
gross hematuria was the cardinal initial symptom in 73.3% of patients (Wu et al, 2004). The 
male to female ratio is reported to be 1:1.7~3.5. Female predominance among these patients 
is uniformly found in the reports from Taiwan and China (Liao et al, 2004; Wu et al, 2004; Li 
et al, 2009; Wang et al, 2010). However, in our early report, although uremic patients were at 
greater risk of developing urologic cancer, UC was uncommon among the renal transplant 
recipients (Chen et al, 1995). 
2.2 Carcinogenesis of urothelial carcinoma in renal transplant recipients 
Among the general population, only 5% of UC arise in the upper urinary tract (UUT) and 
only 2.5% involved bilaterally. UUT-UC is restricted to the renal pelvis in 58% of cases, 35% 
in the ureter, especially in the distal ureter. Many environmental factors have been reported 
to contribute to the development of these cancers. Some are quite similar to bladder cancer-
associated factors related to occupational and environmental exposure such as tobacco, 
industrial dye and certain aromatic amines, etc, while others are more specific to the 
carcinogenesis of the UC such as analgesic, Balkan endemic nephropathy (BEN), Chinese 
herb nephropathy (CHN) or association with Blackfoot disease (BFD) (Hall et al, 1998; Colin 
et al, 2009). In Western countries, analgesic nephropathy (AN) is implicated to contribute to 
development of UC following renal transplantation. UC occurred more frequently in the AN 
group (2.8%) than these in the control group (0.49%) (Swindle et al, 1998). In Taiwan, older 
age at kidney transplantation, female recipient, compound analgesics usage, Chinese herb 
usage, underground water intake and low educational status were the significant risk 
factors for the development of de novo UC (Wang et al, 2010; Liao et al, 2004).  
2.2.1 Chinese herb nephropathy (Aristolochic acid nephropathy) 
Chinese herbs nephropathy after taking a slimming regimen including Chinese herbs 
contaminated with Aristolochia fangchi was reported by Belgium groups. These patients 
experinced a rapid progression to renal failure compared with other interstitial 
nephropathies. Many patients developed UC (Vanherweghem et al, 1993; Reginster et al, 
1997; Cosyns et al, 1998). Aristolochic acid contained in Chinese herbs has been proved to be 
nephrotoxic and carcinogenic (Thon et al, 1995). Li et al from China reported a 2-center 
cohort of 1,612 renal transplant recipients, the patients with aristolochic acid nephropathy 
(AAN) had significantly higher incidence of UC (52.9% vs 0.46% in the control group) (Li et 
al, 2009). Among these patienst, 88.9% involved the upper urinary tract (37.5% bilateral, 
62.5% unilateral). It was more common to see UC cases in the female patients (male to 
female ratio of 1:3.5). These are very similar to the happenings in Taiwan, i.e., high 
incedence of UC in the upper urinary tract and female predominence (Hung et al, 2007; Liao 
et al, 2004; Kang et al, 2004; Kao et al, 2003). Bilateral nephroureterectomy has been a 
standard procedure for these patients. Synchronous UC in bilateral upper urinary tracts was 
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confirmed in 36.7% of cases (Wu et al, 2004). Among the patients with bilateral upper tract 
UC, only 25% had bilateral abnormalities in preoperative image studies (Liao et al, 2004).  
High incidence rate of UUT-UC has been described in some rural areas of the Balkans after 
year 1950, but it has been decreased significantly in recent 20 years (Markovic et al, 2005). 
Bilateral involvement (8–10%) and female predominance are the unique characterictics in 
these patients with BEN which are quite similar to the cases with CHN. Several studies have 
shown the carcinogenic potential of aristolochic acid contained in Aristolochia fangchi 
(contamination in some Chinese herbs) and Aristolochia clematis (a plant popularly present 
in the farm field of the Balkans) (Arlt et al, 2007; Laing et al, 2006; Nortier et al, 2000; 
Consyns et al, 1999). Debelle et al. proposed to combine BEN and CHN under one name, i.e., 
aristolochic acid nephropathy (Debelle et al, 2008). Chen et al reported an incresed risk for 
the professional personels working with Chinese herb medicine to develop chronic renal 
failure and urinary tract cancer. The age-adjusted relative risks of these professional 
personels to develop urinary tract cancer were 3.81 for male and 5.86~9.32 for female 
subjects. This finding supports the hypothesis that urinary tract cancer in Chinese herbalists 
could be related to the long-term exposure of aristolochic acid -containing herbal medicines 
(Chen et al, 2009; Yang et al, 2009). Lai et al using the reimbursement database of National 
Health Insurance from Taiwan to study 4594 patients and 174,701 control subjects (Lai et al, 
2010). There was a statistically significant linear dose–response relationship between the 
cumulative dose of aristolochic acid and the risk of developing urinary tract cancer. 
Consumption of aristolochic acid–containing Chinese herbal medicine was associated with 
an increased risk of developing cancer of the urinary tract in a dose-dependent manner and 
it is independent of arsenic exposure. 
2.2.2 Arsenic intoxication 
An unusually high incidence of UUT-UC has been described in Taiwan. It occurred in the 
south-west part of Taiwan where the population was particularly susceptible to the 
development of UUT-UC which represented 20–25% of all UC cases. This area corresponds 
to the endemic area of Blackfoot disease (BFD), which is known to be a thromboangiitis of 
lower limbs leading to gangrene. The majority of cases required amputation of lower limbs. 
Contamination of drinking water with arsenic has been considered to be the reason for this 
endemic disease. The cases of UUT-UC in the endemic area of BFD are characterized by 
female predominance (male to female ratio of 1:2) and more ureteral tumors (twice as 
common as the renal pelvis tumors) (Tan et al, 2008; Yang et al, 2002; Chiou et al 2001, 
Chiang et al, 1993). The prevalence of UC in the BFD endemic area improved significantly 
after the government modernized the water supply system. However, for some reasons, the 
prevalence of UC in this area is still higher than other parts of Taiwan (Yang et al, 2005; 
Yang et al, 2002). Arsenic exposure is associated with an increased risk of UC. UC patients 
had a significantly higher sum of measured urinary arsenic species including inorganic 
arsenic, monomethylarsonic acid and dimethylarsinic acid (Pu et al, 2002; Chung et al, 2008). 
Arsenic intoxication also involves the formation of DNA adducts and DNA damage (Kato et 
al, 1994; Schwerdtle et al, 2003). Association between inorganic arsenic and UC risk focused 
on the total arsenic ingested from drinking water had been reported (Pu et al, 2002). Subjects 
of low exposure, were still observed to have higher UC risk in subjects with unfavorable 
urinary arsenic profile, i.e., pooreer function of arsenic methylation. The primary 
methylation index (PMI) was defined as the ratio between monomethylarsonic acid and 
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inorganic arsenic. Secondary methylation index (SMI) was defined as the ratio between 
dimethylarsinic acid and monomethylarsonic acid. Unfavorable PMI and SMI levels indicate 
an increased risk of developing UC, especially in non-smokers although smoking has been 
well documented to cause carcionogesis of UC (Zeegers et al, 2000). Undetectable or 
negligible environmental arsenic still plays an important role (Chung et al, 2008). The 
arsenic levels allowed in drinking water is not greater than 5μg/L. The WHO established 
the water quality guidelines for drinking water which included the arsenic levels to be 
undetectable to less than 10μg/L (WHO 1996/1998). Actually, the average arsenic 
concentration in Taipei City, the capital of Taiwan, is ranged from undetectable level to 4.0 
μg/L. Smoking is associated with an increased risk of UC in a dose dependent manner 
(Kato et al, 1994). Arsenic contamination in drinking water and smoking are synergestic in 
the carcinogesis of UC (Chung et al, 2008).  
2.2.3 Role of virus in the carcinogenesis of urothelial carcinoma 
Polyoma virus (PV), BK virus (BKV), human papillomavirus may play a role in the 
pathogesis of UC following renal transplantation. There is lack of data to indicate a 
definitive association between BKV and human cancers (Noel et al, 1994; Husain et al, 2009; 
Abend et al, 2009; Wang et al, 2009; Roberts et al, 2008; Chen et al, 2010). Presence of 
polyoma virus in the biopsy specimen may mimick high grade transitional cell carcinoma 
(Seftel et al, 1996). 
2.2.4 Urothelial carcinoma in hemodialysis patients and renal transplant recipients 
In Taiwan, UC is the most common type of urological cancer in patients with end stage renal 
disease (Chang et al, 2007). The cumulative incidence of UC was between 0.77% to 1.7% in 
hemodialysis patients and 3.1% to 4.1% in renal transplant recipients. The cases of UC in 
hemodialysis patients and renal transplant recipients have similar characteristics of BEN, 
CHN and BFD. As compared with the incidence of UC in the general population of Taiwan 
(10.09/100,000), the standardized incidence ratio of UC in hemodialysis is very high (48.2). 
Women and middle-aged patients had a higher risk. Physicians who are taking care of 
hemodialysis patients and renal transplant recipients should be highly alert with presence of 
hematuria which warrants detailed study of the entire urinary system and image study of 
the native and transplanted kidneys (Wang et al, 2010; Tai et al, 2009; Liao et al, 2004). Only 
19.4% of patients had history of long-term consumption of Chinese herbs and 3.1% had 
history of using analgesic compounds (Wang et al, 2011). Contamination of drinking water 
is considered to be another carcinogenic factor.  
3. Treatment of Urothelial carcinoma after kidney transplantation 
Patients with upper tract lesions are recommended to undergo bilateral nephroureterectomy 
and bladder cuff resection in one session or in separate sessions (Glassman et al, 2001; Kao et 
al, 2004; Zhang et al, 2009). Whether postoperative intravesical instillation of 
chemotherapeutic agents reduces the incidence of bladder recurrence is debating. Wu et al 
reported that intravesical instillation of epirubicin or mitomycin C appeared to be effective 
in preventing bladder recurrence and in prolonging time to first bladder recurrence (Wu et 
al, 2010). Transurethral resection of the bladder tumor is indicated in patients with 
concomitant or superficial bladder lesions. Intravesical chemotherapy is started after 
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transurethral resection and immunosuppressants are adjusted (Li et al, 2008). Laparoscopic 
bilateral nephroureterectomy and bladder cuff excision can be performed safely and gives 
similar oncologic results in experinced hands (Chen et al, 2003; Liao et al, 2004). 
Laparoscopic bilateral nephroureterectomy can be performed in a single session without 
repositioning of the patient if a specially designed inflatable cuff is used (Chueh et al, 2002). 
Retroperitoneal laparoscopic nephroureterectomy with bladder cuff excision can be safely 
performed by combining cystoscopic resection with open transperitoneal dissection. This 
might be a safe and feasible alternative for native UUT-UC ipsilateral to a transplanted kidney 
(Ye et al, 2010). Lymphovascular invasion was reported to be the only significant predictor of 
cancer specific survival in the univariate and multivariate analyses (Chung et al, 2009). The 
benefit of routine lymphadenectomy during nephroureterectomy of UC is debatable. The 
benefit of conversion from calcineurin inhibitors to mammalian targe of rapamycin (mTOR) 
inhibitors (proliferation signal inhibitors) is another debating issue. Many patients experinced 
recurrence of UC after bilateral nephroureterctomy and conversion to mTOR inhibitors 
(Chung et al, 2008; Wang et al 2008; Hu et al, 2009). Systemic chemotherapy can be performed 
on these patients safely and effectively (Matzkies et al, 2000; Lin et al, 2006).  
4. Conclusion  
UC is the leading cause of malignancy in renal transplant recipeints in some Asian countries 
such as China, Iran, Taiwan, Thailand, etc. It is characterized with female predominance, 
frequent bilateral upper urinary tract lesions. The pathogenesis of UC in renal transplant 
recipients is still under investigation. Aristolochic acid, arsenic intoxication, smoking and 
some virus may play important and complicated roles. Transplant physicians should be 
very alert with hematuria, hydronephrosis of native urinary tract which frequently 
implicates presence of UC. Bilateral nephroureterectomy in a single session or in separate 
sessions is recommended 
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